ICH E2A

E555157

ICH E2A is an International Council for Harmonisation guideline that standardizes clinical safety data management and expedited reporting of adverse drug reactions in clinical trials.

Try in SPARQL Jump to: Statements Referenced by

Statements (46)

Predicate Object
instanceOf ICH guideline
pharmacovigilance guideline
regulatory guideline
abbreviationOf International Council for Harmonisation guideline E2A NERFINISHED
addresses assessment of causality for adverse drug reactions
follow-up information for safety reports
reporting of fatal or life-threatening events
reporting of unexpected serious adverse drug reactions
sponsor responsibilities for safety reporting
aimsTo provide consistent definitions for safety data in clinical trials
reduce duplication of safety reporting requirements across regions
appliesTo clinical trials
defines adverse drug reaction
adverse event
expedited report
life-threatening adverse drug reaction
medically important serious event
serious adverse drug reaction
serious adverse event
unexpected adverse drug reaction
focusesOn clinical safety data management
expedited reporting of adverse drug reactions
fullTitle Clinical Safety Data Management: Definitions and Standards for Expedited Reporting NERFINISHED
implementedIn European Union pharmacovigilance legislation
Japan regulatory safety reporting requirements
United States FDA safety reporting regulations for clinical trials
issuedBy International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use NERFINISHED
language English
objective harmonisation of clinical safety reporting requirements
improvement of protection of clinical trial subjects
partOf ICH E2 clinical safety guidelines series NERFINISHED
regulatoryArea human medicines
relatedTo ICH E2B
ICH E2C
ICH E2D
ICH E2E
scope interventional clinical studies
investigational medicinal products in clinical trials
standardizes criteria for expedited reporting
minimum information for safety reports
terminology for clinical safety reporting
timelines for expedited reporting
usedBy clinical trial sponsors
pharmaceutical companies
pharmacovigilance professionals
regulatory authorities

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.